Cerevel Therapeutics (CERE) Stock Price, News & Analysis

Company Overview

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $44.96 to $44.96
• 50-Day Range: $40.30 to $44.96
• 52-Week Range: $19.59 to $44.99
• Volume: N/A
• Average Volume: 1.71 million shs
• Market Capitalization: $8.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Hold

Cerevel Therapeutics Stock Analysis - MarketRank™

Cerevel Therapeutics scored higher than 1% of companies evaluated by MarketBeat, and ranked 942nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Cerevel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cerevel Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.59) to ($2.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cerevel Therapeutics is -16.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cerevel Therapeutics has a P/B Ratio of 12.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CERE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cerevel Therapeutics does not currently pay a dividend.

Dividend Growth

Cerevel Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CERE.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Cerevel Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cerevel Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.10% of the stock of Cerevel Therapeutics is held by insiders.

Percentage Held by Institutions

87.73% of the stock of Cerevel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CERE Stock Analysis - Frequently Asked Questions

How were Cerevel Therapeutics' earnings last quarter?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($0.61) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.02.

Who are Cerevel Therapeutics' major shareholders?

Top institutional shareholders of Cerevel Therapeutics include Westchester Capital Management LLC, Walleye Trading LLC, LMR Partners LLP and Wolverine Asset Management LLC. Insiders that own company stock include Bain Capital Investors Llc, Perceptive Advisors Llc, Ronald C Renaud Jr, N Anthony Coles, Kenneth Dipietro, Paul D Burgess, Mark Bodenrader, Susan Altschuller, Ramiro Sanchez, John Renger, Scott Akamine, Abraham Ceesay and Deval L Patrick.
View institutional ownership trends.

What other stocks do shareholders of Cerevel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerevel Therapeutics investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), First Solar (FSLR) and Datadog (DDOG).

Company Calendar

• Last Earnings: 11/01/2023
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Coal & Consumable Fuels
• Current Symbol: NASDAQ:CERE
• CUSIP: 15677310
• CIK: 767884
• Web: ceres.net
• Phone: 844-304-2048
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $45.00
• High Stock Price Target: $45.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-432,840,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -98.94%
• Return on Assets: -45.07%

Debt

• Debt-to-Equity Ratio: 0.60
• Current Ratio: 10.22
• Quick Ratio: 10.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.71 per share
• Price / Book: 12.12

Miscellaneous

• Outstanding Shares: 182,200,000
• Free Float: 172,903,000
• Market Cap: $8.19 billion
• Optionable: Optionable
• Beta: 1.40